{
    "clinical_study": {
        "@rank": "158112", 
        "acronym": "iTAPP", 
        "arm_group": [
            {
                "arm_group_label": "placebo (left) / aprepitant (right)", 
                "arm_group_type": "Other", 
                "description": "placebo (on defined treatment area on left side of the body) / aprepitant (on defined treatment area on right side of the body)"
            }, 
            {
                "arm_group_label": "aprepitant (left) / placebo (right)", 
                "arm_group_type": "Other", 
                "description": "aprepitant (on a treatment area on the left side of the body) / placebo (on a treatment area on the right side of the body)"
            }
        ], 
        "brief_summary": {
            "textblock": "Topical Aprepitant in Prurigo Patients - An Exploratory Phase IIa Trial With Topically\n      Applied Aprepitant in Patients With Prurigo"
        }, 
        "brief_title": "Topical Aprepitant in Prurigo Patients", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pruritus", 
        "condition_browse": {
            "mesh_term": [
                "Prurigo", 
                "Pruritus"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with Prurigo suffering from chronic pruritus\n\n          -  Disease duration > six month\n\n          -  Therapy refractory to at least two previous antipruritic treatments with topical,\n             intralesional or systemic corticosteroids, or other immunosuppressants,\n             antihistamines, antipsychotics, antidepressants, anticonvulsants and/or\n             UV-irradiation\n\n          -  Adult male or female patients, aged 18 to 80 years\n\n        Exclusion Criteria:\n\n          -  Concomitant medications that are primarily metabolized through Cytochrome P450 3A4\n\n          -  Applied topical antihistamines, corticosteroids or mast cell stabilizers to the skin\n             less than 3 weeks prior to Visit 1 (Screening) or during the course of the trial\n\n          -  UV-irradiation during the last 6 weeks prior to Visit 1 (Screening)\n\n          -  Prescribed systemic medications are limited\n\n          -  Clinically significant abnormalities in Blood analyses\n\n          -  Anamnestic excessive use of alcohol or tobacco or drugs\n\n          -  Presence of active tumor disease or history of malignancies within five years prior\n             to Visit 1 (Screening)\n\n          -  Known or suspected hypersensitivity to component(s) of investigational products\n\n          -  Within the last 30 days or current participation in any other interventional clinical\n             trial\n\n          -  Subjects who have received treatment with any non-marketed drug substance (i.e., an\n             agent which has not yet been made available for clinical use following registration)\n             within the last 6 month\n\n          -  Previously enrolled/randomised in this clinical trial\n\n          -  In the opinion of the investigator, the subject is unlikely to comply with the\n             Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state)\n\n          -  Females who are pregnant, of child-bearing potential and wishing to become pregnant\n             during the trial or are breast feeding\n\n          -  Females of child-bearing potential with positive pregnancy test\n\n          -  Subjects (or their partner) not using an adequate method of contraception (according\n             to national requirements, as applicable)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963793", 
            "org_study_id": "LP0066-1019"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "placebo (left) / aprepitant (right)", 
                    "aprepitant (left) / placebo (right)"
                ], 
                "description": "Aprepitant gel (10 mg/g)", 
                "intervention_name": "Aprepitant", 
                "intervention_type": "Drug", 
                "other_name": "Aprepitant gel"
            }, 
            {
                "arm_group_label": [
                    "placebo (left) / aprepitant (right)", 
                    "aprepitant (left) / placebo (right)"
                ], 
                "description": "gel without active component", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "aprepitant gel vehicle"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aprepitant"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pruritus", 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "contact": {
                "email": "martin.metz@charite.de", 
                "last_name": "Martin Metz, Prof. Dr.", 
                "phone": "+49 (0) 30 450518", 
                "phone_ext": "972"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "D-10117"
                }, 
                "name": "Allergie-Zentrum-Charit\u00e9, Charit\u00e9 - Universit\u00e4tsmedizin Berlin"
            }, 
            "investigator": {
                "last_name": "Martin Metz, Prof.Dr.med", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Topical Aprepitant in Prurigo Patients An Exploratory Phase IIa Trial With Topically Applied Aprepitant in Patients With Prurigo", 
        "overall_contact": {
            "email": "claudia.miranda@leo-pharma.com", 
            "last_name": "Claudia Miranda Foca-Fuchs", 
            "phone": "+49 (0)6102 201-0", 
            "phone_ext": "-207"
        }, 
        "overall_official": {
            "affiliation": "Allergie-Centrum-Charit\u00e9, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Charit\u00e9platz1, D-10117 Berlin", 
            "last_name": "Maurer (ICI) Marcus, Prof. Dr. med.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To investigate the efficacy of topical treatment with aprepitant on pruritus compared to placebo, after 4 weeks of treatment using VAS (Visual Analogue Score)", 
            "measure": "efficacy of topical aprepitant treatment", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963793"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess efficacy of topical applied aprepitant on the status of the skin condition compared to placebo, after 4 weeks of treatment using patient global assessment and clinical score", 
                "measure": "efficacy of topical applied aprepitant", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "To assess long-term effect (e.g., duration of action, duration of reduction of pruritus) of topical applied aprepitant in comparison to placebo, after a follow up period of 2 weeks at the end of the treatment", 
                "measure": "long-term effect of topical applied aprepitant", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "To assess effect of topical applied aprepitant on skin structures in comparison to placebo, after 4 weeks of treatment using TEWL (Transepidermal Water Loss)", 
                "measure": "effect of topical applied aprepitant on skin structures", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}